Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
暂无分享,去创建一个
Matthias Egger | Marcel Zwahlen | Andrew G Renehan | M. Zwahlen | M. Egger | A. Renehan | S. O'dwyer | C. Minder | S. Shalet | Stephen M Shalet | Sarah T O'Dwyer | Christoph Minder
[1] E. Riboli,et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden , 2002, Cancer Causes & Control.
[2] E. Rimm,et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[3] E. Riboli,et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.
[4] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[5] R. Shi,et al. Insulin-like growth factor-I and prostate cancer: a meta-analysis , 2001, British Journal of Cancer.
[6] Douglas G Altman,et al. Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research , 2002, Statistics in medicine.
[7] Meir J. Stampfer,et al. Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .
[8] X. Shu,et al. Insulin-like growth factors and breast cancer risk in Chinese women. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[9] Andrew G Renehan,et al. Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[10] R. Krajcik,et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[11] S. London,et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. , 2002, Journal of the National Cancer Institute.
[12] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[13] J. Ketelslegers,et al. Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.
[14] N. Probst-Hensch,et al. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai , 2001, British Journal of Cancer.
[15] M. Spitz,et al. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[16] S. Mohan,et al. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.
[17] R. Wieczorek,et al. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. , 1995, Endocrinology.
[18] I. G. Fantus,et al. Insulin and related factors in premenopausal breast cancer risk , 2004, Breast Cancer Research and Treatment.
[19] C. McCaig,et al. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin , 2002, Journal of Cell Science.
[20] F. Berrino,et al. Fasting glucose is a risk factor for breast cancer: a prospective study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[21] N. Skakkebaek,et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.
[22] H. Langberg,et al. Physical capacity influences the response of insulin-like growth factor and its binding proteins to training. , 2002, Journal of applied physiology.
[23] R. Shore,et al. Serum insulin‐like growth factor‐I and breast cancer , 2000, International journal of cancer.
[24] David J Hunter,et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.
[25] D. Clemmons,et al. Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.
[26] E. Riboli,et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. , 2000, Journal of the National Cancer Institute.
[27] E. Riboli,et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden , 2002, Gut.
[28] L. Hennighausen,et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. , 2002, Cancer research.
[29] R. Baxter,et al. Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.
[30] J. Khosravi,et al. Immunoassay of insulin-like growth factor-binding protein-3 (IGFBP-3): new means to quantifying IGFBP-3 proteolysis. , 2000, The Journal of clinical endocrinology and metabolism.
[31] J. Frystyk,et al. Free insulin‐like growth factors (IGF‐I and IGF‐II) in human serum , 1994, FEBS letters.
[32] L. Ellis,et al. Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.
[33] A. Renehan,et al. Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .
[34] C. Mantzoros,et al. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] T. Fears,et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[36] M. Spitz,et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. , 1999, Journal of the National Cancer Institute.
[37] C. Potten,et al. High‐risk colorectal adenomas and serum insulin‐like growth factors , 2001, The British journal of surgery.
[38] Douglas G. Altman,et al. Systematic reviews in health care : meta-analysis in context , 2008 .
[39] S. Greenland,et al. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. , 1992, American journal of epidemiology.
[40] W. Willett,et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[41] N. Black,et al. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.
[42] S. Feig. IARC Handbooks of Cancer Prevention , 2003 .
[43] A. McTiernan. Intervention studies in exercise and cancer prevention. , 2003, Medicine and science in sports and exercise.
[44] T. Rohan,et al. Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.
[45] Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. , 2000, The Journal of clinical endocrinology and metabolism.
[46] E. Metter,et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[47] I. McCutcheon,et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.
[48] M. Pollak. Insulin-like growth factor physiology and cancer risk. , 2000, European journal of cancer.
[49] W. Bodmer,et al. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] E. Riboli,et al. A prospective study of insulin‐like growth factor‐I, IGF‐binding proteins‐1, ‐2 and ‐3 and lung cancer risk in women , 2001, International journal of cancer.
[51] S. Hankinson,et al. Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[52] M. Stampfer,et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.
[53] T. Key,et al. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[54] M. Spitz,et al. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[55] D. Dunger,et al. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. , 2002, Journal of the National Cancer Institute.
[56] E. Giovannucci. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. , 2001, The Journal of nutrition.
[57] B. Stewart,et al. World Cancer Report , 2003 .
[58] C. Mantzoros,et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.